Using new data from US and global markets, we revisit market risk premium predictability by equity anomalies. We apply a repertoire of machine-learning methods to forty-two countries to reach a simple conclusion: anomalies, as such, cannot predict aggregate market returns. Any ostensible evidence from the USA lacks external validity in two ways: it cannot be extended internationally and does not hold for alternative anomaly sets—regardless of the selection and design of factor strategies. The predictability—if any—originates from a handful of specific anomalies and depends heavily on seemingly minor methodological choices. Overall, our results challenge the view that anomalies as a group contain helpful information for forecasting market risk premia.
No takes yet. Share an insight, caveat, or question.
Cakici et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: